Phaseline

Companies › Silence Therapeutics

Silence Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SLN124
siRNA targeting TMPRSS6 mRNA
TMPRSS6Phase 1Polycythemia VeraMar 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05499013SLN124Phase 1Polycythemia VeraOncologyMar 2030

From the company's SEC filings

Cash and short-term investments of $72m on 2026-06-30; operating cash outflow about $29m a year; runway about 30 months at that burn, to Jan 2029

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

TMPRSS6 (1)

Companies with the same targets

Ono Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.